Biểu đồ giá cổ phiếu BDTX
BDTX Cổ tức
Black Diamond Therapeutics Inc
$2.94
-1.67%
$-0.05
Khi đóng cửa: May 11, 16:00:00 GMT-4
$2.93
-0.34%
$0
Phiên sau giờ: May 11, 18:39:00 GMT-4
Quay lại
Black Diamond Therapeutics Inc (BDTX) Cổ tức
Thống kê chính
Giá đóng cửa trước
$2.99
Giá mở cửa
$3.03
Phạm vi ngày
$2.92 - $3.18
Phạm vi 52 tuần
$1.53 - $4.94
Khối lượng
1.2M
Khối lượng trung bình
789.5K
Tỷ suất cổ tức
--
EPS (TTM)
0.38
Vốn hóa thị trường
$167.8M
BDTX là gì?
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
